Drug interactions with at least 50% change in the exposure to dabigatran or rivaroxaban
Mechanism . | Dabigatran . | Rivaroxaban . | ||
---|---|---|---|---|
Interacting drug . | Δ exposure, % . | Interacting drug . | Δ exposure, % . | |
P-gp inhibition | Ketoconazole* | 150 | Ketoconazole* | 160 |
Quinidine | 53 | |||
Amiodarone | 60 | |||
Verapamil | ≃ 50† | |||
P-gp induction | Rifampicin | −67 | Rifampicin | −50 |
St John's wort | ND | St John's wort | ND | |
CYP3A4 inhibition | Ketoconazole* | 160 | ||
Clarithromycin | 50 | |||
Ritonavir | 50 | |||
CYP3A4 induction | Rifampicin | −50 | ||
St John's wort | ND |
Mechanism . | Dabigatran . | Rivaroxaban . | ||
---|---|---|---|---|
Interacting drug . | Δ exposure, % . | Interacting drug . | Δ exposure, % . | |
P-gp inhibition | Ketoconazole* | 150 | Ketoconazole* | 160 |
Quinidine | 53 | |||
Amiodarone | 60 | |||
Verapamil | ≃ 50† | |||
P-gp induction | Rifampicin | −67 | Rifampicin | −50 |
St John's wort | ND | St John's wort | ND | |
CYP3A4 inhibition | Ketoconazole* | 160 | ||
Clarithromycin | 50 | |||
Ritonavir | 50 | |||
CYP3A4 induction | Rifampicin | −50 | ||
St John's wort | ND |